Difference between revisions of "Carmustine wafer, polifeprosan 20 (Gliadel wafer)"
(Created page with "Also known as polifeprosan 20 with carmustine implant. ==General information== Class/mechanism: Biodegradable copolymer matrix (polifeprosan 20) embedded with carmustine, a nitr...") |
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
||
| Line 6: | Line 6: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref> | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 06:40, 13 May 2012
Also known as polifeprosan 20 with carmustine implant.
General information
Class/mechanism: Biodegradable copolymer matrix (polifeprosan 20) embedded with carmustine, a nitrosourea which alkylates DNA and RNA and inhibits several key enzymatic processes by carbamoylation of amino acids in proteins. Each Gliadel wafer is 1.45 cm in diameter and 1 mm thick and contains 192.3 mg copolymer and 7.7 mg carmustine. Exposure to the surgical resection cavity results in hydrolyzation of anhydride bonds of the copolymer, which releases carmustine.[1][2][3]
Route: implanted wafer
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)[4]
- Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)[5]
References
- ↑ 1.0 1.1 Carmustine wafer, polifeprosan 20 (Gliadel) package insert
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) package insert (locally hosted backup)
- ↑ Gliadel manufacturer's website
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)